Business & Finance
NANOBIOTIX collects revenues of EUR31.9,000 for Q2 2019
22 July 2019 -

Nanomedicine company NANOBIOTIX (ISIN: FR0011341205) disclosed on Friday that its revenue was EUR31.9,000 for the second quarter of 2019.

The company said the revenues were generated by the cross-charge to its partners related to shared contract research organization costs pursuant to our license and collaboration agreement.

As of 30 June 2019, the company announced cash availability of EUR54.9m.

In addition, the company announced the first European market approval for Hensify (NBTXR3) for locally advanced Soft Tissue Sarcoma as well as organisational changes to reinforce necessary competencies as strategic priorities evolve and to help accelerate its longstanding mission to significantly improve outcomes for patients.